<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="50733">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02445742</url>
  </required_header>
  <id_info>
    <org_study_id>BOS-IIG-01</org_study_id>
    <nct_id>NCT02445742</nct_id>
  </id_info>
  <brief_title>CML Treated With Bosutinib After Relapse</brief_title>
  <acronym>BOSTRO</acronym>
  <official_title>Single Nucleotide Polymorphism Association With Response and Toxic Effects in Patients With Ph+ CP-CML Treated With Bosutinib After Relapse to Previous Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PETHEMA Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PETHEMA Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, open label, multicenter, phase II study evaluating correlation of SNPs with
      efficacy and toxicity in patients treated with Bosutinib. A total of 50 patients with
      previously treated Ph+ chronic phase CML will be included in the study
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety measured as adverse event gradation</measure>
    <time_frame>2 years</time_frame>
    <description>Safety measured as graded adverse events described on common terminology criteria for adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy measured as response rate</measure>
    <time_frame>2 years</time_frame>
    <description>Eficaccy measured as response rate to treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Chronic Myeloblastic Leukaemia</condition>
  <arm_group>
    <arm_group_label>Bosutinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 mg/day of Bosutinib during the study until disease progression, unacceptable toxicity, or withdrawal of consent occurs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bosutinib</intervention_name>
    <description>500 mg/day of Bosutinib during the study until disease progression, unacceptable toxicity, or withdrawal of consent occurs</description>
    <arm_group_label>Bosutinib</arm_group_label>
    <other_name>Bostro</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed and dated informed consent form.

          -  Patients with chronic Ph + CML who presented a non-optimal response at 3 months prior
             to ITK treatment (imatinib, nilotinib, dasatinib). It is defined as a non-optimal
             response:

        BCR-ABL&gt; 10% per qRT-PCR (IS) at 3 months of initiation of treatment. BCR / ABL ≥ 1% per
        qRT-PCR (IS) at 6 months of initiation of treatment. BCR / ABL&gt; 0.1% qRT-PCR (IS) at 12
        months of initiation of treatment. BCR-ABL1&gt; 0.1% qRT-PCR (IS) at any time after 12 months
        of treatment initiation.

          -  ECOG Performance Status of 0 or 1.

          -  Recovery at Grade 0-1, or at the baseline value of any pretreatment toxicity, except
             for alopecia. Cases with significant toxicity will be analyzed individually by the
             study coordinators

          -  Able to take daily oral capsules

          -  Adequate bone marrow function:

               1. Absolute neutrophil count &gt; 1000/mm3 (&gt;1000 x109/L)

               2. Platelets ≥ 100,000/mm3 (&gt;100 x109/L)

               3. absent any platelet transfusions during the preceding 14 days.

          -  Adequate hepatic, and renal function:

               -  AST/ALT ≤ 2.5 × upper limit of normal (ULN) or ≤ 5 × ULN if attributable to
                  liver involvement of leukemia

               -  Total bilirubin ≤ 1.5 × ULN

               -  Creatinine ≤ 1.5 × ULN

          -  Age &gt; 18 years

          -  Willingness of male and female subjects, who are not surgically sterile or
             postmenopausal, to use reliable methods of birth control (oral contraceptives,
             intrauterine devices, or barrier methods used with a spermicide) for the duration of
             the study and for 30 days after the last dose of Bosutinib.

        Exclusion Criteria

          -  Subjects with Philadelphia chromosome and bcr-abl negative CML.

          -  Overt leptomeningeal leukemia. Subjects must be free of CNS involvement for a minimum
             of 2 months. Subjects with symptoms of CNS involvement must have a diagnostic lumbar
             puncture prior to study enrollment.

          -  Subjects with extramedullary disease only.

          -  Prior stem cell transplantation.

          -  Major surgery within 14 days or radiotherapy within 7 days before the first dose of
             Bosutinib (recovery from any previous surgery should be complete before day 1)

          -  A history of a clinically significant ventricular arrhythmia, congenital or acquired
             prolonged QT interval, a baseline QTcF &gt; 0.47 sec (average of triplicate readings) or
             unexplained syncope, uncontrolled or symptomatic congestive heart failure (CHF)
             within 3 months, or myocardial infarction (MI) within 6 months.

          -  Concomitant use of or need for medications known to prolong the QT interval

          -  Uncorrected hypomagnesemia or hypokalemia due to potential effects on the QT interval

          -  Recent (within 30 days of study entry) or ongoing clinically significant
             gastrointestinal disorder (e.g., malabsorption, short bowel syndrome, bleeding, or
             grade &gt;1 diarrhea, nausea or emesis lasting more than 2 days, despite adequate
             medical therapy)

          -  Pregnant or breastfeeding women

          -  Evidence of serious active infection, or significant medical or psychiatric illness

          -  Known seropositivity to HIV, or current acute or chronic Hepatitis B or Hepatitis C
             (antigen positive), cirrhosis, hypokalemia (any grade), or clinically significant
             abnormal laboratory finding that would, in the investigator's judgment, make the
             subject inappropriate for this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luis Felipe Casado, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>PETHEMA Foundation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luis Felipe Casado, Dr</last_name>
    <email>fcasadom@sescam.jccm.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>José Luis Steegmann, Dr</last_name>
    <email>jlsteegmann@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>C. H. U. de Gran Canaria Dr. Negrín</name>
      <address>
        <city>Gran Canaria</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maite Gómez Casares, Dr</last_name>
      <email>mgomcasf@gobiernodecanarias.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>C. H. Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Santiago Osorio, Dr</last_name>
      <email>sanosorio2000@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>C. U. La Paz - H. U. La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raquel de Paz, Dr</last_name>
      <email>depazraquel@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J Valentín García Gutiérrez, Dr</last_name>
      <email>jvalentingg@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. U. de la Princesa</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Luis Steegmann, Dr</last_name>
      <email>jlsteegmann@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. U. Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Luis López Lorenzo, Dr</last_name>
      <email>JLLopez@fjd.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joaquin Martinez, Dr</last_name>
      <email>jmartinezlo1967@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>C. H. Regional de Málaga , H. General</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Jiménez Velasco, Dr</last_name>
      <email>a.jimenez.velasco@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. U. Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrés Novo, Dr</last_name>
      <email>andres.novo@ssib.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>C. Asistencial U. de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fermín Sánchez Guijo, Dr</last_name>
      <email>ferminsg@usal.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>C. H. U. de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Pérez Encinas, Dr</last_name>
      <email>manuelperez@aehh.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. Virgen de la Salud</name>
      <address>
        <city>Toledo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Felipe Casado, Dr</last_name>
      <email>Fcasadom@sescam.jccm.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clínica Quirón Zaragoza S.A.</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pilar Giraldo, Dr</last_name>
      <email>giraldocastellano@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 11, 2017</lastchanged_date>
  <firstreceived_date>May 6, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Myeloblastic Leukaemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia, Myeloid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
